About US
Contact us
-
M&As this week: Sygnis, Incyte, AptuitBiotechnology companySygnis AGplans to acquire proteomics company Expedeon to expand its product portfolio and develop sales in the US and European markets. The company has announced its plans to rai2016/5/13
-
Report: Heart failure market to witness a compound annual growth rate of 13.7%The heart failure market is set to grow to $11.8bn by 2025 from $3.2bn in 2015, at a compound annual growth rate of 13.7%, according to a report by GlobalData. According to the report, titled 'Pharma2016/5/13
-
LDC, Boehringer and Max Planck partner to discover treatment of SchizophreniaGerman companies Lead Discovery Centre (LDC), Boehringer Ingelheim International and Max Planck Innovation have signed an agreement to provide Boehringer with the option to receive exclusive rights to2016/5/12
-
NICE approves GSK's lupus drug BenlystaThe National Institute for Health and Care Excellence (NICE) has reportedly approved GlaxoSmithKline's (GSK) Benlysta for the treatment of lupus. Earlier in 2011, NICE rejected Benlysta as it believe2016/5/12
-
NICE recommends PTC's Translarna to treat Duchenne muscular dystrophyThe UK's National Institute for Health and Care Excellence (NICE) has recommended PTC Therapeutics' Translarna (ataluren) for the treatment of Duchenne muscular dystrophy (DMD) caused by a nonsense mu2016/5/11
-
EC grants approval for Bristol-Myers' Opdivo to treat renal cell carcinomaBristol-Myers Squibb has obtained approval from the European Commission (EC) for its Opdivo (nivolumab) for previously treated advanced renal cell carcinoma (RCC). RCC is the most common type of kidn2016/5/11
-
Gilead's Descovy receives FDA approval to treat HIVAmerican biopharmaceutical company Gilead Sciences has secured approval from the US Food and Drug Administration (FDA) for Descovy (emtricitabine 200mg/tenofovir alafenamide 25mg, F/TAF) to treat pati2016/5/10
-
EMA committee recommends approval of Amicus' Galafold to treat Fabry diseaseThe European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended a marketing authorisation of Amicus Therapeutics' Galafold (migalastat) to treat Fabry disea2016/5/10
-
Eli Lilly receives FDA Priority Review approval for olaratumabAmerican pharmaceutical company Eli Lilly and Company has received Priority Review approval from the US Food and Drug Administration (FDA) for its biologics license application (BLA) for olaratumab.2016/5/9
-
M&As this week: Precision for Medicine and VeristatPharmaceutical and healthcare companyPrecision for Medicinehas acquired Applied Immunology, a custom cell-based and immunoassay solutions provider. Precision for Medicine expects that the move will h2016/5/9